Application of PD-L1, PD-L2, CD30, CD23 and BCL-6 in Diagnosis and Prognostic Evaluation of Primary Mediastinal Large B-cell Lymphoma

Código QR

Application of PD-L1, PD-L2, CD30, CD23 and BCL-6 in Diagnosis and Prognostic Evaluation of Primary Mediastinal Large B-cell Lymphoma

Objective To explore the application value of treatment-related markers PD-L1, PD-L2, CD30, CD23, BCL-2, BCL-6, MUM1 and GATA3 in the diagnosis and prognostic evaluation of primary mediastinal B-cell lymphoma(PMBL). Methods A retrospective study was conducted on 34 patients diagnosed with PMBL, and...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	YUAN Ting, CAO Zheng, LIU Xiuyun, ZHENG Bo, FENG Xiaoli
Formato:	article
Lenguaje:	ZH
Publicado:	Magazine House of Cancer Research on Prevention and Treatment 2021
Materias:	lymphoma mediastinum immunohistochemistry pd-l1 pd-l2 cd30 cd23 bcl-6 Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/83fbdd36e92f4720acb2da0f5986a5ef
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Large cell morphology, CMYC+ tumour cells, and PD-1+ tumour cell/intense PD-L1+ cell reactions are important prognostic factors in nodal peripheral T-cell lymphomas with T follicular helper markers
por: Yasuhito Mihashi, et al.
Publicado: (2021)

Correlation between schistosomiasis and CD8+ T cell and stromal PD-L1 as well as the different prognostic role of CD8+ T cell and PD-L1 in schistosomal-associated colorectal cancer and non-schistosomal-associated colorectal cancer
por: Weixia Wang, et al.
Publicado: (2021)

Different Induction of PD-L1 (CD274) and PD-1 (CD279) Expression in THP-1-Differentiated Types 1 and 2 Macrophages
por: Lai CY, et al.
Publicado: (2021)

Immunoexpression of PD-L1 and PD-1 and Its Clinicopathological Correlation in Urothelial Carcinomas
por: Utpal Kumar, et al.
Publicado: (2021)

Treatment-Related Adverse Events with PD-1 or PD-L1 Inhibitors: A Systematic Review and Meta-Analysis
por: Yixi Zhang, et al.
Publicado: (2021)

Hiding in the dark: pan-cancer characterization of expression and clinical relevance of CD40 to immune checkpoint blockade therapy
por: Chi Yan, et al.
Publicado: (2021)

The Potential Advantage of Targeting Both PD-L1/PD-L2/PD-1 and IL-10–IL-10R Pathways in Acute Myeloid Leukemia
por: Laura Jimbu, et al.
Publicado: (2021)

Stomach cancer. Clinical significance of the expression of key components of PD-1/PD-L1 immune checkpoint
por: Olga V. Kovaleva, et al.
Publicado: (2021)

Bone Marrow-Resident Vδ1 T Cells Co-express TIGIT With PD-1, TIM-3 or CD39 in AML and Myeloma
por: Franziska Brauneck, et al.
Publicado: (2021)

EGCG Inhibits Tumor Growth in Melanoma by Targeting JAK-STAT Signaling and Its Downstream PD-L1/PD-L2-PD1 Axis in Tumors and Enhancing Cytotoxic T-Cell Responses
por: Dinoop Ravindran Menon, et al.
Publicado: (2021)

Impaired Cytotoxic CD8<sup>+</sup> T Cell Response in Elderly COVID-19 Patients
por: Jaana Westmeier, et al.
Publicado: (2020)

Various Uses of PD1/PD-L1 Inhibitor in Oncology: Opportunities and Challenges
por: Zhitao Li, et al.
Publicado: (2021)

Modern approaches in the first line treatment of CD30-positive peripheral T-cell lymphomas
por: Irina V. Poddubnaya, et al.
Publicado: (2021)

Clinical observation of the efficacy of PD‐1/PD‐L1 inhibitors in the treatment of patients with advanced solid tumors
por: Miao Wang, et al.
Publicado: (2021)

New Insights into the Role of PD-1 and Its Ligands in Allergic Disease
por: Miguel Angel Galván Morales, et al.
Publicado: (2021)

Tumor response as defined by iRECIST in gastrointestinal malignancies treated with PD-1 and PD-L1 inhibitors and correlation with survival
por: Peiyi Xie, et al.
Publicado: (2021)

Comparison of Serum Levels of Soluble CD26 and CD30 in Patients with Brucellosis and Controls
por: AR Rafiei,, et al.
Publicado: (2009)

What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 2: Clinic–Pathologic Correlations
por: Andrea Palicelli, et al.
Publicado: (2021)

High Inflammatory Tendency Induced by Malignant Stimulation Through Imbalance of CD28 and CTLA-4/PD-1 Contributes to Dopamine Neuron Injury
por: Dong L, et al.
Publicado: (2021)

Kaposi’s Sarcoma-Associated Herpesvirus Increases PD-L1 and Proinflammatory Cytokine Expression in Human Monocytes
por: Kurtis M. Host, et al.
Publicado: (2017)

CD8+ T Lymphocytes Immune Depletion and LAG-3 Overexpression in Hodgkin Lymphoma Tumor Microenvironment Exposed to Anti-PD-1 Immunotherapy
por: Jean-Marie Michot, et al.
Publicado: (2021)

POLAROGRAPHIC CHARACTERISTICS AND THERMODYNAMICS APPLIED IN [Cd - L-AMINO ACIDATES - VITAMIN-B7] TERNARY SYSTEM
por: KHAN,FARID, et al.
Publicado: (2013)

What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 1: Focus on Immunohistochemical Results with Discussion of Pre-Analytical and Interpretation Variables
por: Andrea Palicelli, et al.
Publicado: (2021)

Reconstitution of Monocyte Subsets and PD-L1 Expression but Not T Cell PD-1 Expression in Obstructive Sleep Apnea Patients upon PAP Therapy
por: Christina Polasky, et al.
Publicado: (2021)

Applicability and interpretation of HER2/Neu & PD-L1 stains in gastrointestinal tract tumours
por: Prasenjit Das, et al.
Publicado: (2021)

Alphataxin, a Small-Molecule Drug That Elevates Tumor-Infiltrating CD4+ T Cells, in Combination With Anti-PD-1 Therapy, Suppresses Murine Renal Cancer and Metastasis
por: Cynthia L. Bristow, et al.
Publicado: (2021)

Respiratory Syncytial Virus Infection Induces Expression of Inducible Nitric Oxide Synthase, CD3, and CD8 in Naturally Occurring Pneumonia in Lambs
por: Yaman Turan, et al.
Publicado: (2021)

New opportunities of systemic therapy of CD30-positive primary cutaneous T-cell lymphomas
por: Irina V. Poddubnaya, et al.
Publicado: (2020)

COMPARISON OF SERUM LEVELS OF CD26 AND CD30 IN CHRONIC RENAL FAILURE AND HEMODIALYTIC PATIENTS
por: AR Rafiei,, et al.
Publicado: (2008)

Dl-3-N-Butylphthalide Presents Anti-Cancer Activity in Lung Cancer by Targeting PD-1/PD-L1 Signaling
por: Jiang Q, et al.
Publicado: (2021)

Conditional Deletion of Pdcd1 Identifies the Cell-Intrinsic Action of PD-1 on Functional CD8 T Cell Subsets for Antitumor Efficacy
por: Sukanya Raghavan, et al.
Publicado: (2021)

Mediastinal lymphoma-induced superior vena cava syndrome and chylopericardium in a pregnant lady: a case report
por: Omar S Obeidat, et al.
Publicado: (2020)

Universal extracellular vesicles and PD-L1+ extracellular vesicles detected by single molecule array technology as circulating biomarkers for diffuse large B cell lymphoma
por: Ji-Wei Li, et al.
Publicado: (2021)

Role of PD-L1 in licensing immunoregulatory function of dental pulp mesenchymal stem cells
por: Rosanna Di Tinco, et al.
Publicado: (2021)

Potential Biomarkers for the Efficacy of PD-1-PD-L Blockade in Cancer
por: Grecea M, et al.
Publicado: (2021)

Efficacy of PD‐1/PD‐L1 inhibitors in patients with non‐small cell lung cancer and brain metastases: A real‐world retrospective study in China
por: Jiamin Sheng, et al.
Publicado: (2021)

The relationship between blood-based tumor mutation burden level and efficacy of PD-1/PD-L1 inhibitors in advanced non-small cell lung cancer: a systematic review and meta-analysis
por: He Ba, et al.
Publicado: (2021)

Interplay between IL-10, IFN-γ, IL-17A and PD-1 Expressing EBNA1-Specific CD4<sup>+</sup> and CD8<sup>+</sup> T Cell Responses in the Etiologic Pathway to Endemic Burkitt Lymphoma
por: Catherine S. Forconi, et al.
Publicado: (2021)

TIM‐3 as a potential exhaustion marker in CD4+ T cells of COVID‐19 patients
por: Zahra Modabber, et al.
Publicado: (2021)

Plasmatic Levels of HSP90α at Diagnosis: A Novel Prognostic Indicator of Clinical Outcome in Advanced Lung Cancer Patients Treated With PD-1/PD-L1 Inhibitors Plus Chemotherapy
por: Shubin Chen, et al.
Publicado: (2021)